-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Regains Compliance with Nasdaq Listing Standards
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Announces 1:10 Reverse Share Split
-
443,917 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

